The cancer genomic sequencing data suggests that residues in the ATP-binding site and CH-domain (i.e., UPF2 interacting interface) of the UPF1 protein are frequently mutated, and we assessed the effects of those mutations on UPF1using in silico methodologies. The gene discussed is UPF2; the disease is cancer.